Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$81.11

0.11 (0.14%)

07:08
10/05/16
10/05
07:08
10/05/16
07:08

Eli Lilly to acquire veterinary vaccine portfolio from Boehringer Ingelheim

Eli Lilly subsidiary Elanco U.S. announced an agreement with Boehringer Ingelheim Vetmedica to acquire a portfolio of U.S. canine, feline and rabies vaccines, as well as a fully integrated manufacturing and R&D site. The sale price of $885M includes the estimated cost of acquired inventory. The deal is conditioned on antitrust approval and closing of the Boehringer Ingelheim asset swap transaction with Sanofi that was signed in June. The current BIVI vaccine portfolio has experienced consistent revenue growth over the past three years. The sale to Elanco is anticipated to close by early 2017 subject to approval by the Federal Trade Commission, and other contingencies.

  • 07

    Oct

  • 25

    Oct

  • 06

    Nov

LLY Eli Lilly
$81.11

0.11 (0.14%)

09/21/16
JANY
09/21/16
DOWNGRADE
Target $36
JANY
Neutral
Janney downgrades Clovis with buyout speculation at 'fever pitch'
Janney Capital analyst Roy Buchanan downgraded Clovis Oncology (CLVS) to Neutral from Buy with an increased fair value estimate of $36. Clovis is up 17c to $35.00 in late morning trading. In a research note partially titled, "May Be Right, May Be Crazy - M&A Speculation At Fever Pitch," Buchanan says there is a "finite chance" that Clovis will need to market its PARP inhibitor rucaparib by itself. He believes a late-2016 approval for rucaparib is likely. The analyst attributes his increased fair value estimate to "acquisition optionality." Reports of Takeda's (TKPYY) reserving up to $15B for acquisitions and Medivation's (MDVN) takeout have given Clovis shares a lift, Buchanan tells investors. The analyst adds that rumors surfaced yesterday of potential interest in the company from Eli Lilly (LLY).
09/27/16
GSCO
09/27/16
UPGRADE
Target $95
GSCO
Buy
Eli Lilly upgraded to Buy from Neutral at Goldman
Goldman analyst Jami Rubin upgraded Eli Lilly to Buy and increased its price target to $95 from $89 saying the company is entering a long lasting period of accelerating topline and earnings growth driven by its late stage pipeline. Rubin projects $12.5B of new product sales by 2020 and double digit earnings growth over the next five years, even without Sola. The analyst sees a 35%, up from 25%, probability of success for Sola with a bull case scenario that can lead to almost $7.5B in peak sales and "super charge" earnings. Even without Sola, Rubin sees favorable risk/reward given durability of earnings and said it is the least exposed to above-CPI price increases.
09/27/16
09/27/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Eli Lilly (LLY) upgraded to Buy from Neutral at Goldman with analyst Jami Rubin saying the company is entering a long lasting period of accelerating topline and earnings growth driven by its late stage pipeline. 2. AutoZone (AZO) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Simeon Gutman saying the company is at a positive inflection in 7 year and older vehicles, which is strongly correlated to same-store-sales. 3. Consolidated Edison (ED) upgraded to Hold from Sell at Evercore ISI with analyst Greg Gordon saying the joint settlement proposal filed in the CECONY rate case mitigates downside risk. 4. Crown Holdings (CCK) upgraded on multiple catalysts at BMO Capital with analyst Mark Wilde citing valuation, his belief that the company will resume returning cash to shareholders in 2017, and his belief that the company's results should be boosted by " a wave of domestic and offshore expansion projects." 5. Francesca's (FRAN) upgraded to Buy from Hold at Stifel with analyst Richard Jaffe saying the company's "appealing merchandise" makes it very likely that its sales will grow going forward. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/28/16
BERN
09/28/16
NO CHANGE
BERN
Biogen likely to benefit from Lilly Alzheimer's drug results, says Bernstein
Bernstein analyst Aaron Gal says that the results of a trial of Eli Lilly's (LLY) Alzheimer's drug, solanezumab, due out in late 2016 or early 2017, are likely to impact perceptions of Biogen's (BIIB) Alzheimer's drug, aducanumab. The analyst expects Lilly's solanezumab "to show at least directional evidence" of cognitive improvement, although he is "less convinced" that the impact will be clearly statistically significant. The best results from Biogen's perspective will be if Lilly's drug shows "marginal success," according to Gal. However, statistically significant results are also good for Biogen, as they will show that reducing amyloid beta does mitigate Alzheimer's symptoms, the analyst stated. And if Lilly's drug completely fails, Biogen's drug "could well succeed," given the significant differences between them, wrote Gal,who gives Biogen's aducanumab a 65% chance of success. He keeps a $345 price target and Outperform rating on Biogen.

TODAY'S FREE FLY STORIES

DIS

Disney

$99.57

0.97 (0.98%)

06:59
09/26/17
09/26
06:59
09/26/17
06:59
Periodicals
Disney streams theme-park events in new prototype stores, Bloomberg says »

Walt Disney is opening…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

SPX

S&P 500

06:59
09/26/17
09/26
06:59
09/26/17
06:59
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LCI

Lannett

$17.10

-0.3 (-1.72%)

06:58
09/26/17
09/26
06:58
09/26/17
06:58
Hot Stocks
Lannett revceives approval for Dexmethylphenidate Hydrochloride Tablets »

Lannett announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDX

Market Vector Gold Miners

$23.83

0.36 (1.53%)

06:58
09/26/17
09/26
06:58
09/26/17
06:58
Technical Analysis
Market Vector Gold Miners: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$124.53

1.29 (1.05%)

06:58
09/26/17
09/26
06:58
09/26/17
06:58
Technical Analysis
SPDR Gold Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXON

Axovant Sciences

$24.25

-0.74 (-2.96%)

06:58
09/26/17
09/26
06:58
09/26/17
06:58
Hot Stocks
Breaking Hot Stocks news story on Axovant Sciences »

Axovant Sciences trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUGT

Direxion Gold Miners Bull

$35.50

1.72 (5.09%)

06:57
09/26/17
09/26
06:57
09/26/17
06:57
Technical Analysis
Direxion Gold Miners Bull: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNUG

Direxion Daily Jr Gld Mnrs Bull 3X Shrs

$20.07

1 (5.24%)

06:57
09/26/17
09/26
06:57
09/26/17
06:57
Technical Analysis
Direxion Daily Jr Gld Mnrs Bull 3X Shrs: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DUST

Direxion Daily Gold Miners Bear 3X ETF

$23.21

-1.2 (-4.92%)

06:57
09/26/17
09/26
06:57
09/26/17
06:57
Technical Analysis
Direxion Daily Gold Miners Bear 3X ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JDST

Direxion Daily Junior Gold Miners Index Bear 3x Shares

$50.66

-2.87 (-5.36%)

06:56
09/26/17
09/26
06:56
09/26/17
06:56
Technical Analysis
Direxion Daily Junior Gold Miners Index Bear 3x Shares: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VXX

iPath S&P 500 VIX Short-Term Futures

$41.28

0.03 (0.07%)

06:56
09/26/17
09/26
06:56
09/26/17
06:56
Technical Analysis
iPath S&P 500 VIX Short-Term Futures: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XIV

VelocityShares Daily Inverse VIX Short-Term ETN

$92.69

-0.14 (-0.15%)

06:55
09/26/17
09/26
06:55
09/26/17
06:55
Technical Analysis
VelocityShares Daily Inverse VIX Short-Term ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TVIX

VelocityShares Daily 2x VIX Short-Term ETN

$12.60

0.06 (0.48%)

06:55
09/26/17
09/26
06:55
09/26/17
06:55
Technical Analysis
VelocityShares Daily 2x VIX Short-Term ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYE

Myers Industries

$19.70

-0.3 (-1.50%)

06:55
09/26/17
09/26
06:55
09/26/17
06:55
Syndicate
Breaking Syndicate news story on Myers Industries »

Myers Industries files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SVXY

ProShares Short VIX Short-Term Futures

$89.07

-0.04 (-0.04%)

06:55
09/26/17
09/26
06:55
09/26/17
06:55
Technical Analysis
ProShares Short VIX Short-Term Futures: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXMD

TherapeuticsMD

$6.06

-0.11 (-1.78%)

06:54
09/26/17
09/26
06:54
09/26/17
06:54
Syndicate
TherapeuticsMD 12.4M share Spot Secondary priced at $5.65 »

JPMorgan acted as sole…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 03

    Nov

  • 26

    Sep

MB

Mindbody

$26.10

-0.8 (-2.97%)

06:54
09/26/17
09/26
06:54
09/26/17
06:54
Conference/Events
Mindbody to host analyst day »

Analyst day to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

USO

United States Oil Fund

$10.55

0.31 (3.03%)

06:53
09/26/17
09/26
06:53
09/26/17
06:53
Technical Analysis
United States Oil Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBRA

Sabra Health Care

$22.33

0.12 (0.54%)

06:53
09/26/17
09/26
06:53
09/26/17
06:53
Syndicate
Sabra Health Care 16M share Spot Secondary priced at $21.00 »

The deal range was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 26

    Sep

XOP

SPDR Oil Exploration and Production Fund

$33.98

0.94 (2.85%)

06:53
09/26/17
09/26
06:53
09/26/17
06:53
Technical Analysis
SPDR Oil Exploration and Production Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGAZ

VelocityShares 3x Inv Natural Gas ETN

$24.81

0.55 (2.27%)

06:53
09/26/17
09/26
06:53
09/26/17
06:53
Technical Analysis
VelocityShares 3x Inv Natural Gas ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TAST

Carrols Restaurant

$11.55

-0.1 (-0.86%)

06:52
09/26/17
09/26
06:52
09/26/17
06:52
Downgrade
Carrols Restaurant rating change  »

Carrols Restaurant…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UGAZ

VelocityShares 3x Long Natural Gas ETN

$11.35

-0.27 (-2.32%)

06:52
09/26/17
09/26
06:52
09/26/17
06:52
Technical Analysis
VelocityShares 3x Long Natural Gas ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWZ

MSCI Brazil Index

$41.79

-0.94 (-2.20%)

06:52
09/26/17
09/26
06:52
09/26/17
06:52
Technical Analysis
MSCI Brazil Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFA

iShares MSCI EAFE Index Fund

$68.00

-0.39 (-0.57%)

06:51
09/26/17
09/26
06:51
09/26/17
06:51
Technical Analysis
iShares MSCI EAFE Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.